AN2 Therapeutics, Inc. — Director's Dealing 2023

Jun 10, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AN2 Therapeutics, Inc. (ANTX)
CIK: 0001880438
Period of Report: 2023-06-07

Reporting Person: Zakrzewski Joseph S (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-07	Stock Option
(right to buy)	$5.91	A	23742	Acquired	2033-06-06	Common Stock (23742)	Direct

Footnotes

F1: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.